Reply to L. Kennedy et al

Affiliations

Comment

Charles L Shapiro et al. J Clin Oncol. 2018.

. 2018 Apr 1;36(10):1052-1053.

doi: 10.1200/JCO.2017.77.2749. Epub 2018 Feb 1.

¹ Charles L. Shapiro, Icahn School of Medicine at Mt Sinai, New York, NY; and James P. Moriarty and Bijan Borah, Mayo Clinic, Rochester, MN.

No abstract available

Comment on

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Shapiro CL, et al. J Clin Oncol. 2017 Dec 10;35(35):3949-3955. doi: 10.1200/JCO.2017.73.7437. Epub 2017 Oct 12. J Clin Oncol. 2017. PMID: 29023215 Free PMC article. Clinical Trial.
Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases.
Kennedy L, Bhatta S, Hechmati G, Buchanan J. Kennedy L, et al. J Clin Oncol. 2018 Apr 1;36(10):1051. doi: 10.1200/JCO.2017.77.0115. Epub 2018 Feb 1. J Clin Oncol. 2018. PMID: 29389236 No abstract available.